相关实验视频
Updated: Feb 28, 2026

08:18
Preparation of Naringenin Solution for In Vivo Application
Published on: August 10, 2021
3.9K
长期低剂量酸盐管理改善了2型糖尿病大鼠胰岛素敏感组织的抗氧化防御系统
Fatemeh Ghorbani1, Majid Shokri1, Sajad Jeddi1
1Endocrine Physiology Research Center, Research Institute for Endocrine Molecular Biology, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Endocrinology, diabetes & metabolism
|February 26, 2026
概括
在患有2型糖尿病 (T2D) 的老鼠中长期使用酸盐可降低氧化应激. 这项研究发现,酸盐补充剂改善了肝脏,肌肉和皮层脂肪组织中的抗氧化剂水平,这表明它具有保护作用.
科学领域:
- 生物化学 生物化学
- 内分泌学 在内分泌学.
- 生理学 生理学 生理学
背景情况:
- 2型糖尿病 (T2D) 的特点是氧化应激增加,导致胰岛素抵抗.
- 研究酸盐对T2D氧化应激标记物的影响对于理解潜在的治疗策略至关重要.
研究的目的:
- 评估酸盐在患有T2D的雄性大鼠肝脏,肌底肌肉 (SM) 和皮层脂肪组织 (eAT) 中的长期抗氧化作用.
主要方法:
- 鼠被分为控制,控制+酸盐,T2D和T2D+酸盐组.
- 通过高脂肪饮食和链毒素诱导T2D; 酸盐在饮用水中服用6个月.
- 测量了组织中的催化酶 (CAT),总抗氧化能力 (TAC),减少的谷氨 (GSH),甲酸 (MDA) 和氧化代谢物 (NOx) 的水平.
主要成果:
- 酸盐在肝脏和eAT中增加了CAT,并在T2D大鼠的肝脏中恢复了TAC和GSH的减少.
- 在SM中,酸盐降低了MDA,恢复了CAT. 在eAT中,酸盐增加了CAT和TAC.
- 在NOx和CAT,TAC和GSH之间发现了正相关性,在NOx和MDA之间发现了负相关性.
结论:
- 长期使用低剂量的酸盐证明了对T2D大鼠的关键代谢组织中氧化应激的保护作用.
- 酸盐补充剂可能是减轻T2D相关氧化损伤的可行策略.
相关概念视频
Antianginal Drugs: Nitrates and β-Blockers
1.8K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.8K
Coronary Artery Disease II: Pathophysiology
815
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
815
Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Diabetes Mellitus: Type 2 and Gestational
5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
739
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
739

